Comparative efficacy of prophylactic protocols in reducing perioperative nausea and vomiting during video-assisted thoracoscopic radical resection of lung cancer

Weiguang Zhang,Zhimin Shen,Junfei Jiang,Shujing Zhu,Peipei Zhang,Sui Chen,Mingqiang Kang
DOI: https://doi.org/10.1038/s41598-024-59687-z
IF: 4.6
2024-04-30
Scientific Reports
Abstract:Lung cancer, a global mortality leader, often necessitates Video-Assisted Thoracoscopic (VATS) surgery. However, post-operative nausea and vomiting (PONV) is common, highlighting a need for effective management and prevention strategies in this context. A retrospective case–control study at Fujian Medical University Union Hospital evaluated patients undergoing VATS radical resection of lung cancer between May and September 2022. Patients were categorized based on PONV prevention methods, and data encompassing demographics, surgical history, and postoperative adverse events s were analyzed to assess the association between prophylactic protocols and PONV incidence. The Netupitant and Palonosetron Hydrochloride (NEPA) group showed a significant reduction in PONV occurrences post-surgery compared to Ondansetron (ONDA) and Control groups, emphasizing NEPA's efficacy in alleviating PONV symptoms (P < 0.05). Furthermore, following VATS radical resection of lung cancer, NEPA markedly reduced the intensity of PONV symptoms in patients. Both univariate and multivariate logistic analyses corroborated that NEPA independently reduces PONV risk, with its protective effect also apparent in susceptible populations like females and non-smokers. NEPA utilization markedly reduced both the incidence and severity of PONV in patients undergoing VATS radical resection of lung cancer, serving as an independent protective factor in mitigating PONV risk post-surgery.
multidisciplinary sciences
What problem does this paper attempt to address?
This paper aims to address the issue of postoperative nausea and vomiting (PONV) in lung cancer patients undergoing video-assisted thoracoscopic surgery (VATS) for lung cancer radical resection. Specifically, the study compares the effectiveness of two anti-nausea medications—Netupitant-Palonosetron (NEPA) and Ondansetron (ONDA) in preventing PONV. The study found that NEPA was significantly superior to ONDA in reducing the incidence and severity of PONV, and NEPA also showed potential in reducing side effects such as dizziness. Additionally, the study confirmed the effectiveness of NEPA as an independent protective factor for preventing PONV, with better efficacy observed particularly in women and non-smokers.